NasdaqGS:PCVXBiotechs
Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial
Vaxcyte (PCVX) has dosed the first participant in its Phase 1 trial of VAX-A1, a Group A Strep vaccine candidate. This is a key early step in testing a product aimed at a large unmet medical need.
See our latest analysis for Vaxcyte.
Despite the positive development for VAX-A1, recent share price momentum has been soft, with the stock down 10.66% on a 30 day share price return and 20.16% on a 90 day share price return, while the 1 year total shareholder return of 28.03% and 5 year total...